人民财讯7月31日电，申联生物(688098)7月31日晚间公告，公司与中国农业科学院兰州兽医研究所(简 称"兰研所")等单位签订了《猪口蹄疫O型/A型、猪瘟、伪狂犬病三联疫苗技术开发(合作)合同》及《牛 口蹄疫O型/A型、病毒性腹泻/黏膜病、传染性鼻气管炎三联疫苗技术开发(合作)合同》，共同开发猪用 口蹄疫等三种疫病多联多价疫苗及牛用口蹄疫等三种疫病多联多价疫苗，合作各方按照协议约定任务和 分工，各自承担相关费用，合作研发项目产生的技术成果及知识产权归公司及兰研所两方共同享有。 ...

智通财经APP讯，申联生物(688098.SH)公告，公司与中国农业科学院兰州兽医研究所等单位签订了 《猪口蹄疫O型/A型、猪瘟、伪狂犬病三联疫苗技术开发(合作)合同》及《牛口蹄疫O型/A型、病毒性 腹泻/黏膜病、传染性鼻气管炎三联疫苗技术开发(合作)合同》，共同开发猪用口蹄疫等三种疫病多联多 价疫苗及牛用口蹄疫等三种疫病多联多价疫苗，合作各方按照协议约定任务和分工，各自承担相关费 用，合作研发项目产生的技术成果及知识产权归公司及兰研所两方共同享有。 ...

7月24日，市场继续大涨，近4400只个股上涨，914只个股下跌，79只个股涨停，1只个股跌停。 高位股，雅下水电概念恒立钻具30CM4连板，深水规院20CM4连板，中国电建、保利联合、西藏天路、高争民爆、西宁特钢、山河智能4连板，中设股份上 演"地天板"录得4连板。海南相关个股凯撒旅业6天3板、康芝药业20CM涨停，千亿权重中国中免涨停。创新药南京新百2连板，年报增长彩虹集团2连板。 | | 代码 | 名称 | 几天几板 价格 | 涨幅% 涨停分析 | 换手率 | 成交额 | 首次涨停时间 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 002542 | 中化岩土 | 6天4板 5.01 | +10.11% 岩土工程+低空经济+国企+中 | 24.22% | 20.51亿 | 09:42:45 | | 2 | 601669 | 中国电建 | 4连板 7.45 | +10.04% 雅 水电概念+水电风电+抽水 | 17.09% | 158.57亿 | 10:45:00 | | 3 | 002037 | 保利联合 | 4连板 14.19 | + ...

Group 1 - The company announced that its wholly-owned subsidiary, Jinyu Baoling, received clinical trial approval for an African swine fever subunit vaccine from the Ministry of Agriculture and Rural Affairs [1] - The vaccine is jointly developed by the Institute of Biophysics of the Chinese Academy of Sciences and China National Pharmaceutical Group Animal Health Co., Ltd., with Jinyu Baoling as the clinical trial undertaking unit [1] - The total research and development investment for the project is approximately 64 million yuan [1] Group 2 - Due to the complexity of the immune mechanism of the African swine fever virus, there is a risk of failure in the clinical trials [1] - The vaccine must complete clinical trials and obtain registration approval before it can be marketed and sold [1] - The company will monitor subsequent developments and fulfill its information disclosure obligations [1]

Core Insights - Emerging infectious diseases and antimicrobial resistance (AMR) are major global health threats closely linked to zoonotic diseases, requiring improved interdepartmental collaboration and the promotion of innovative solutions [1][2][3] Group 1: Challenges in Disease Control - The need for enhanced collaboration between health, agriculture, and environmental sectors is critical, as 75% of new infectious diseases are zoonotic, with climate change and human activities increasing cross-species transmission risks [3] - The rising antibiotic resistance among bacteria poses significant challenges, as many antimicrobial drugs are losing effectiveness, leading to prolonged treatment periods and potential treatment failures [3][4] - The implementation of the "One Health" concept is gaining consensus among academia, international organizations, and governments to address zoonotic diseases effectively [3][4] Group 2: Innovation and Technology - Advances in genomic sequencing technology for infectious disease monitoring have improved, but commercialization and large-scale application remain challenges [1][8] - Digital technologies, including AI, are seen as transformative for implementing the "One Health" strategy, enhancing monitoring of antibiotic resistance and clinical decision-making [8] - The lack of consensus on high-throughput sequencing technology in veterinary diagnostics highlights the need for cross-departmental integration to overcome monitoring challenges [6][8] Group 3: Funding and Resource Allocation - Sustainable funding is essential for promoting innovative solutions, particularly in low-resource settings, where health budgets are constrained [9] - The World Bank emphasizes the importance of collaborative financing models to support monitoring systems and the "One Health" strategy, involving private sector participation [9]

Group 1 - The first domestically developed nine-valent HPV vaccine, "Cecolin®9," has been approved for market release in China, breaking a long-standing foreign monopoly on the market [2][6] - The incidence and mortality rates of cervical cancer in China have been rising over the past 30 years, with a notable trend towards younger demographics [3] - The nine-valent HPV vaccine provides over 98% protection against persistent infections from HPV types not covered by the bivalent vaccine, with a 100% protection rate against cervical infections [4] Group 2 - The development of the nine-valent HPV vaccine took 18 years, involving significant breakthroughs in technology and extensive clinical trials with over 11,000 participants [4] - The approval of the nine-valent HPV vaccine marks a significant advancement in China's biopharmaceutical sector, establishing the country as the second in the world, after the United States, capable of independently supplying high-cost HPV vaccines [6] - The World Health Organization's global strategy to accelerate the elimination of cervical cancer aligns with China's action plan, which emphasizes promoting HPV vaccination as a key objective [6]

Core Viewpoint - 康乐卫士 is currently in a loss-making state with no products commercialized, reporting a revenue of 885,600 yuan in 2024, a decrease of 50.24% year-on-year, and a net profit of -357 million yuan, down 18.51% year-on-year [1] Group 1: Financial Performance - In 2024, 康乐卫士 reported a revenue of 885,600 yuan, a decline of 50.24% compared to the previous year [1] - The net profit attributable to the parent company was -357 million yuan, representing a year-on-year decrease of 18.51% [1] - The operating cash flow was -125 million yuan, indicating a reliance on external financing for working capital [3] Group 2: Research and Development - 康乐卫士 has a total of 9 vaccine candidates in development, including 8 recombinant protein candidates and 1 mRNA candidate [2] - Key products such as the trivalent HPV vaccine and the nine-valent HPV vaccines for both female and male indications have entered Phase III clinical trials [2] - The trivalent HPV vaccine's market approval application has been accepted by the National Medical Products Administration (NMPA) and is included in the priority review process [2] Group 3: Operational Strategy - 康乐卫士 is transitioning towards becoming a commercial pharmaceutical company and has established a production base in Kunming that meets GMP standards, with an annual production capacity of 10 million doses of the trivalent HPV vaccine and 30 million doses of the nine-valent HPV vaccine [2] - The company has introduced a systematic response plan to address the risk of insufficient working capital, which includes accelerating HPV vaccine development and commercialization, optimizing asset utilization, actively seeking financing, and enhancing internal management to reduce costs and increase efficiency [3] Group 4: Recent Developments - In the first quarter of 2024, 康乐卫士 reported a 90.51% decline in revenue, while the net profit attributable to the parent company increased by 18.12% year-on-year [4]